Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography

Moschouris, Hippocrates; Malagari, Katerina; Dimakis, Andreas; Kiakidis, Theodoros; Anagnostopoulou, Anastasia

doi:10.1007/s00270-020-02487-5

Cited by 6 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We evaluated as primary outcome measures the following: number of treated lesions, dose of DC Beads LUMI™, dose of Epirubicin, DC Beads LUMI™ target tumour coverage (LC) according to the percentage of target nodule involvement (LC1 0%-25%, LC2 25%-50%, LC3 50%-75%, LC4 75%-100%), TACE-related complications according to Cardiovascular and Interventional Radiological Society of Europe (CIRSE) classification 12 target lesion's response rate and overall tumour(s) response rates according to modified response evaluation criteria in solid tumours (mRECIST) criteria, with outcomes classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD). 13,14 Liver function laboratory data were assessed pre-and post-procedure.…”

Section: Outcome Measuresmentioning

confidence: 99%

Efficacy and Safety of Transarterial Chemoembolization with DC Beads LUMI in the Treatment of HCC: Experience from a Tertiary Centre

Biondetti,

Lanza,

Carriero

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Purpose The aim of this study was to describe the safety and efficacy profiles of TACE using DC Beads LUMI. Materials and methods We retrospectively analyzed 90 patients with HCC who underwent TACE with DC Bead LUMI™ between November 2018 and November 2020 at Fondazione IRCCS Cà Granda Policlinico Hospital in Milan, Italy. Patient- and tumour-related factors were registered, including the number of treated lesions, dose of DC Beads LUMI™, dose of Epirubicin, DC Beads LUMI™ target tumour coverage (LC) according to the percentage of target nodule involvement (LC1-0%–25%, LC2-25%–50%, LC3-50%–75%, LC4 75%–100%). Treatment efficacy was obtained through reviewing the follow-up imaging for evidence of response in target lesion(s), according to modified response criteria in solid tumours (mRECIST) criteria with the following outcomes: complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD). Safety assessment was based on the quantitative and qualitative recording of the adverse events, classified according to CIRSE classification. Results Seventy-two patients were enrolled, and 95 procedures were carried out. We observed a target tumour response rate at 1 month with CR in 68%, PR in 10.3% 11.8%, SD in 13%, PD in 7.2%, and an overall tumour(s) (whole liver) response at 1 month with CR in 58.9%, PR in 12.6%, SD in 10.5% and PD in 18%. We found a significant association ( p < 0.01) between tumour response CR or CR + PR and the number of the target lesion(s). CIRSE classification grade I and grade II complications were recorded, respectively, in 11 (11.6%) and 6 (6.3%) procedures. No grade III-IV-V complications occurred. Conclusion TACE using DC Beads LUMI is a safe and effective treatment option for patients with HCC.

show abstract

Section: Outcome Measuresmentioning

confidence: 99%

Efficacy and Safety of Transarterial Chemoembolization with DC Beads LUMI in the Treatment of HCC: Experience from a Tertiary Centre

Biondetti,

Lanza,

Carriero

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In the study by Shiozawa et al, CEUS at 3 days after DEB-TACE allowed the early assessment of therapeutic efficacy, with no enhancement and peripheral ring enhancement significantly suggestive of a positive outcome [33]. Moschouris et al reported the utility of CEUS in increasing the sensitivity, specificity, and diagnostic accuracy of CECT after DEB-TACE (80.4%, 88.9%, and 81.8% for CECT and 93.5%, 100%, and 94.5% for CEUS + CECT, respectively) using CEMRI as reference standard [34].…”

Section: Tace and Ceusmentioning

confidence: 99%

Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma

Faccia

Garcovich

Ainora

et al. 2022

Cancers

View full text Add to dashboard Cite

The capacity of contrast-enhanced ultrasound (CEUS) to detect microvessel perfusion has received much attention in cancer imaging since it can be used to evaluate the enhancement patterns of the lesions during all vascular phases in real time, with higher temporal resolution as compared other imaging modalities. A rich body of literature has demonstrated the potential usefulness of CEUS in the assessment of HCC in response to both locoregional and systemic therapies. It is useful to evaluate the efficacy of ablation immediately after treatment to provide guidance for the retreatment of residual unablated tumors. In patients treated with transarterial chemoembolization (TACE), CEUS showed a high degree of concordance with computed tomography and magnetic resonance for the differentiation of responders from non-responders. Dynamic CEUS (D-CEUS) has emerged as a promising tool for the depicting changes in tumor perfusion during anti-angiogenetic treatment that can be associated with tumor response and clinical outcome. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure in different stages of the disease.

show abstract

“…DC Bead LUMI TM (Biocompatibles UK Ltd, UK) is a drug-eluting technology with iodine incorporated into its chemical structure, ensuring that it is permanently radiopaque [97]. Few studies [97][98][99] have been published with radiopaque beads in humans. They showed safety and response rates comparable to non-radiopaque beads, although no randomised or comparative data are available.…”

Section: Radiopaque Beadsmentioning

confidence: 99%

“…They showed safety and response rates comparable to non-radiopaque beads, although no randomised or comparative data are available. Some issues are still under debate, such as the difficulty to ensure reliable imaging follow-up using CT [99] as well as the very different pharmacokinetic profile of drug elution compared to non-radiopaque beads [100]. This would imply that all prior phase I/II data published on doxorubicin-eluting microspheres are not valid with radiopaque beads, which theoretically necessitates specific clinical investigations.…”

Section: Radiopaque Beadsmentioning

confidence: 99%

CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation

Lucatelli

Burrel

Guiu

et al. 2021

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

This CIRSE Standards of Practice document is aimed at interventional radiologists and provides best practices for performing transarterial chemoembolisation. It has been developed by an expert writing group under the guidance of the CIRSE Standards of Practice Committee. It will encompass all technical details reflecting European practice of different TACE procedures (Lp-TACE, DEM-TACE, DSM-TACE, b-TACE) as well as revising the existing literature on the various clinical indications (HCC, mCRC, ICC, NET). Finally, new frontiers of development will also be discussed.

show abstract

Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography

Cited by 6 publications

References 19 publications

Efficacy and Safety of Transarterial Chemoembolization with DC Beads LUMI in the Treatment of HCC: Experience from a Tertiary Centre

Efficacy and Safety of Transarterial Chemoembolization with DC Beads LUMI in the Treatment of HCC: Experience from a Tertiary Centre

Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma

CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation

Contact Info

Product

Resources

About